Comparative pharmacokinetics of a single oral dose of meloxicam in the California sea lion ( Zalophus californianus ) and Pacific harbor seal ( Phoca vitulina richardii )
Journal of Veterinary Pharmacology and Therapeutics · 2024
DOI: 10.1111/jvp.13469 ↗Kurz gefasst
Vergleichsstudie in der Zeitschrift Journal of Veterinary Pharmacology and Therapeutics, 2024. Verfasst von Emily J Trumbull und 5 weiteren Autor:innen. Beteiligte Einrichtung: County of San Diego, San Diego, California, USA. Hauptthemen laut MEDLINE: Meloxicam, Phoca, Anti-Inflammatory Agents, Non-Steroidal, Sea Lions. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 28 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Morris Animal Foundation.
Abstract (Originalsprache)
Pharmacokinetics studies have investigated meloxicam, a non‐steroidal anti‐inflammatory drug, dosing strategies in a wide variety of non‐domestic animals; however, there is no prior study examining well‐founded dosing for pinnipeds. To develop dosing protocols, pharmacokinetic information is needed, with an examination of differences between pinniped species. Apparently, healthy California sea lions ( Zalophus californianus : CSL; n = 13) and Pacific harbor seals ( Phoca vitulina richardii : PHS; n = 17) that had completed rehabilitation were enrolled into a population‐based pharmacokinetic study. Each animal was administered a single oral dose of meloxicam at 0.1 mg/kg, and two blood samples were collected from each animal at varying intervals during a 96‐h study period. Plasma concentrations of meloxicam were determined by high‐pressure liquid chromatography. Data were analyzed with nonlinear mixed effects modeling (Phoenix® NLME™, Certara, St. Louis, MO 63105, USA). The results indicated that in PHS, peak plasma concentration (C max ) was 0.33 μg/mL with an elimination half‐life (K e t½) of 31.53 h. In CSL, C max was 0.17 μg/mL with K e t½ of 32.71 h. All animals enrolled completed the study without outward adverse clinical signs. The elimination half‐life was longer than previously recommended dosing intervals for pinnipeds; however, we cannot speculate in the optimum clinical dose from these results.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- County of San Diego, San Diego, California, USA.
- SeaWorld, San Diego, California, USA.
- College of Veterinary Medicine, North Carolina State University, Raleigh, North Carolina, USA.
- The Marine Mammal Center, Sausalito, California, USA.
- SR3 (SeaLife Response, Rehab, Research), Des Moines, Washington, USA.
ORCID-Profile: Emily J Trumbull, Mark G Papich, Mattison Peters, Emily R Whitmer, Michelle Rivard
Förderung
- Morris Animal Foundation
Zitieren
APA
Trumbull, E. J., Papich, M. G., Peters, M., Whitmer, E. R., Rivard, M., & Field, C. L. (2024). Comparative pharmacokinetics of a single oral dose of meloxicam in the California sea lion ( Zalophus californianus ) and Pacific harbor seal ( Phoca vitulina richardii ). Journal of Veterinary Pharmacology and Therapeutics. https://doi.org/10.1111/jvp.13469
Vancouver
Trumbull EJ, Papich MG, Peters M, Whitmer ER, Rivard M, Field CL. Comparative pharmacokinetics of a single oral dose of meloxicam in the California sea lion ( Zalophus californianus ) and Pacific harbor seal ( Phoca vitulina richardii ). Journal of Veterinary Pharmacology and Therapeutics. 2024. doi:10.1111/jvp.13469
BibTeX
@article{Trumbull2024,
author = {Trumbull, Emily J and Papich, Mark G and Peters, Mattison and Whitmer, Emily R and Rivard, Michelle and Field, Cara L},
title = {Comparative pharmacokinetics of a single oral dose of meloxicam in the California sea lion ( Zalophus californianus ) and Pacific harbor seal ( Phoca vitulina richardii )},
journal = {Journal of Veterinary Pharmacology and Therapeutics},
year = {2024},
doi = {10.1111/jvp.13469}
}
EUVIMED